EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real-world experience with cefepime/zidebactam under compassionate use

Dilip K Dubey, Subramanian Swaminathan, Praveen K Tirlangi, Vishnu Rao Polati, Rajeev Soman, Rasika Sirsat, Abdul Ghafur, Raman Gaikwad, Vasant Nagvekar, Abi S Manesh, Irfana Mohammed, Harshad S Limaye und 35 weitere

Journal of Antimicrobial Chemotherapy · 03.11.2026 · 81 (12)

DOI: 10.1093/jac/dkag324 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 10.11.2026. Verfasst von Dilip K Dubey und 46 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Critical Care Medicine, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh 226030, India. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Cefepime, Cyclooctanes. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options.

Methods

We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes.

Results

Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation.

Conclusions

In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsCefepimeCyclooctanesGram-Negative Bacterial InfectionsAdultAgedFemaleHumansMaleMiddle AgedCompassionate Use TrialsDrug CombinationsGram-Negative BacteriaMicrobial Sensitivity TestsRetrospective StudiesThird Generation CephalosporinsTreatment OutcomePiperidines

Substanzen

Anti-Bacterial AgentsAzabicyclo CompoundsCefepimecefepime-zidebactamCyclooctanesDrug CombinationsThird Generation CephalosporinszidebactamPiperidines

Autor:innen und Institutionen

  • Institute of Critical Care Medicine, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh 226030, India.
  • Department of Infectious Diseases, Gleneagles Global Hospitals, Chennai, Tamil Nadu 600100, India.
  • Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka 576104, India.
  • Department of Infectious Diseases, Apollo Hospital, Jubilee Hills, Hyderabad, Telangana State 500096, India.
  • Department of Infectious Diseases, Jupiter Hospital, Pune, Maharashtra 411045, India.
  • Department of Infectious Diseases, P.D. Hinduja National Hospital & Medical Research Centre, Mumbai, Maharashtra 400052, India.

ORCID-Profile: Nitin Gupta, Umang Agrawal, Manish Soneja, Anjely P Sebastian, William R Miller, Radhika N Sarda, Samuel L Aitken, David van Duin, Thomas P Lodise

Zitieren

APA

Dubey, D. K., Swaminathan, S., Tirlangi, P. K., Polati, V. R., Soman, R., Sirsat, R., Ghafur, A., Gaikwad, R., Nagvekar, V., Manesh, A. S., Mohammed, I., Limaye, H. S., Shah, P. H., Mittal, A., Patil, P. Y., Gupta, N., Agrawal, U., Soneja, M., Sridharan, S., …, & Lodise, T. P. (2026). Real-world experience with cefepime/zidebactam under compassionate use. Journal of Antimicrobial Chemotherapy, 81(12). https://doi.org/10.1093/jac/dkag324

Vancouver

Dubey DK, Swaminathan S, Tirlangi PK, Polati VR, Soman R, Sirsat R, et al. Real-world experience with cefepime/zidebactam under compassionate use. Journal of Antimicrobial Chemotherapy. 2026;81(12). doi:10.1093/jac/dkag324

BibTeX
@article{Dubey2026,
  author = {Dubey, Dilip K and Swaminathan, Subramanian and Tirlangi, Praveen K and Polati, Vishnu Rao and Soman, Rajeev and Sirsat, Rasika and Ghafur, Abdul and Gaikwad, Raman and Nagvekar, Vasant and Manesh, Abi S and Mohammed, Irfana and Limaye, Harshad S and Shah, Pooja H and Mittal, Ankit and Patil, Pratik Y and Gupta, Nitin and Agrawal, Umang and Soneja, Manish and Sridharan, Sowmya and Madan, Surabhi and Mitra, Sandeep K and Sahu, Monalisa and Sunavala, Ayesha J and Toraskar, Kedar K and Singhal, Tanu and Tayade, Ashwini R and Gupta, Neha and Sebastian, Anjely P and Rahulan, Vijil and Narreddy, Suneetha and Ulloa, Erlinda R and Miller, William R and Krishna, Vidya and Savla, Honey S and Sarda, Radhika N and Bansal, Nitin and Inamdar, Shalmali B and Kadnur, Harshith B and Shetty, Siddhant and Deswal, Vikas and Adderson, Elisabeth E and Aitken, Samuel L and van Duin, David and William, Timothy and Shorr, Andrew and Veeraraghavan, Balaji and Lodise, Thomas P},
  title = {Real-world experience with cefepime/zidebactam under compassionate use},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {12},
  doi = {10.1093/jac/dkag324}
}
Kostenlos starten →